Compare Aurora Cannabis Inc (ACB) vs Freeport-McMoRan Inc (FCX) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

FCX trades at $59.27, down 2.77% on the day, with a bearish technical signal but strong fundamentals including a 10.34% net income margin and consistent earnings beats. Recent news highlights copper demand growth from AI and energy transitions, positioning FCX as a key player. Cash flow trends show improving operational performance, though net cash flow remains negative due to heavy investments.

Outlook is positive with a consensus price target of $71.81, implying 21% upside, supported by robust copper demand and expansion projects. Risks include commodity price volatility and execution challenges. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor debt levels and global economic conditions.